Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KT-621, an oral drug, in adults with uncontrolled moderate to severe eosinophilic asthma. This Phase 2b trial aims to understand how well KT-621 works, how safe and tolerable it is, and how the body processes the drug. Participants will be randomly assigned to one of four groups to receive either one of three doses of KT-621 or a matching placebo. Treatment will be given orally, and the study will track changes in lung function and asthma control over 12 weeks. Safety and drug levels in the blood will be monitored through 16 weeks. Throughout the study, participants will attend scheduled visits for lung function tests, asthma symptom questionnaires, and blood tests. Researchers will measure lung function improvement, asthma control, quality of life, treatment side effects, and drug concentration in plasma. The study will last until December 2027, with assessments focused on the 12 to 16-week treatment and monitoring periods.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the immune response and safety of GlaxoSmithKlines investigational chickenpox vaccine and a marketed measles, mumps, and rubella MMR vaccine when given to healthy children aged 12 to 15 months. The study compares these vaccines administered by muscle injection to Mercks chickenpox vaccine given just under the skin. It also assesses the immune response and safety when the GSK vaccines are given together with other routine childhood vaccines. Participants are randomly assigned to receive either the candidate varicella vaccine intramuscularly along with MMR, hepatitis A virus HAV vaccine, and a pneumococcal conjugate vaccine PCV, or the marketed varicella vaccine subcutaneously with the same additional vaccines. The PCV given may be PCV 13, Vaxneuvance, or PCV 20 depending on availability and national recommendations. All vaccines are given on Day 1. Throughout the study, children are monitored for immune responses by measuring antibody levels against varicella zoster virus and MMR antigens at Day 43. Safety is evaluated by tracking any local and systemic reactions in the days following vaccination, as well as any adverse events up to six months after the dose. The study aims to understand both the immune response and safety profile over this period in healthy young children receiving these vaccines.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety of an investigational varicella vaccine VNS Vaccine compared to an approved varicella vaccine called Varivax. This study focuses on healthy children aged 12 to 15 months who have not had chickenpox or received any varicella vaccine before. The goal is to understand how well the new vaccine is tolerated in this young population. Participants will receive one dose of either the investigational varicella vaccine or the marketed Varivax vaccine, both given by injection under the skin. Along with the varicella vaccine, each child will also receive one dose each of measles, mumps, and rubella MMR vaccine, hepatitis A vaccine, and a pneumococcal conjugate vaccine PCV, which may be PCV 13, Vaxneuvance, or PCV 20, depending on availability and national recommendations. All vaccines are given on the first day of the study. During the study, parents will record any side effects their child experiences, particularly those related to the injection site or systemic symptoms like fever, for up to 43 days. Researchers will monitor any adverse events, including serious and medically attended events, for up to 181 days after vaccination. This helps assess the safety and tolerability of the investigational vaccine over a period of about six months.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.
Actively Recruiting
Researchers are evaluating the effectiveness of antigravity treadmill training and body weight-supported treadmill training for rehabilitation in elderly patients aged 60 to 75 years who have recently undergone hip or knee replacement surgery. The study compares these two methods to conventional gait training to see which approach may better support recovery and walking ability after surgery. Participants will be randomly assigned to one of three groups antigravity treadmill training, body weight-supported treadmill training, or conventional rehabilitation. Each group will undergo a 6-week program with five sessions per week. The antigravity treadmill uses air pressure to reduce weight on joints with gradually decreasing support, while the body weight-supported treadmill uses a harness to partially offload weight with a steady level of support. The conventional group receives standard postoperative therapy including gait training and physical therapy techniques. During the study, participants will receive comprehensive daily therapy including kinesitherapy, ergotherapy, and individualized physical therapy procedures. Researchers will assess outcomes such as pain and function using the Western Ontario and McMaster Universities Osteoarthritis Index, balance, mental health, stress, and walking parameters both before and after the 6-week intervention. The total participation period includes baseline assessments and the 6-week therapy program under professional supervision.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new pneumococcal vaccine called PG4 compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC in children and adolescents. The study aims to see how well the new vaccine helps the body fight germs that cause pneumonia, meningitis, and ear infections. It includes children aged 15 months to less than 18 years, some of whom may have previously received pneumococcal vaccines. Participants will be divided into three age groups 15 months to under 2 years, 2 to under 5 years, and 5 to under 18 years. Within each group, participants will be randomly assigned in a 21 ratio to receive a single injection of either the new vaccine PG4 or the existing 20vPnC vaccine, given in the arm or thigh. The study is conducted across multiple countries including the United States and Puerto Rico. Each participant will be involved for about 6 months, attending two clinic visitsone for vaccination and one for follow-upand one telephone follow-up. Blood samples will be collected at visits to measure immune response, and participants will be monitored for local and systemic reactions, adverse events, and serious adverse events throughout the study period. The study evaluates immune system protein levels and antibody activity one month after vaccination to compare the vaccines effects.